PROBIÓTICOS EN EL TRATAMIENTO DEL MIELOMA MÚLTIPLE: UNA REVISIÓN
DOI:
https://doi.org/10.47820/recima21.v5i6.5340Palabras clave:
Enfermedades oncohematológicas. Microbioma intestinal. Microbiología.Resumen
El mieloma múltiple (MM) es la segunda neoplasia hematológica más común, caracterizada por la proliferación descontrolada de células plasmáticas, lo que resulta en complicaciones como anemia, lesiones óseas e insuficiencia renal. Estudios sugieren que la microbiota intestinal puede influir en la progresión del MM y en la respuesta al tratamiento. En este contexto, los probióticos, conocidos por sus beneficios para la salud intestinal, presentan potencial terapéutico para el tratamiento del MM, mejorando la microbiota y la respuesta inmunológica. Por lo tanto, el objetivo fue realizar una revisión sistemática a través del Methodi Ordinatio sobre el potencial uso de probióticos en el tratamiento del mieloma múltiple. Las búsquedas se llevaron a cabo en el mes de abril de 2024, en las bases de datos: Embase, Scopus y Web of Science. No se utilizaron intervalos temporales. La búsqueda arrojó un total de 104 publicaciones, de las cuales 2 cumplieron con los criterios de selección. Las publicaciones datan de 2018 y 2024. El mayor valor InOrd fue alcanzado por la revista Cell Metabolism, mientras que la revista Probiotics and Antimicrobial Proteins presentó el mayor número de citas. Ambas revistas tienen un alto factor de impacto. Evidencias preliminares sugieren que los prebióticos pueden desencadenar efectos inmunomoduladores y antiinflamatorios, mejorando la condición general de los pacientes. Estudios indican que el desequilibrio de la microbiota intestinal puede influir en la progresión de la enfermedad y en la eficacia del tratamiento, resaltando la necesidad de más investigaciones en este campo.
Descargas
Referencias
ABBASI, A. et al. Antigenotoxicity and cytotoxic potentials of cell-free supernatants derived from Saccharomyces cerevisiae var. boulardii on HT-29 human colon cancer cell lines. Probiotics and Antimicrobial Proteins, v. 15, n. 6, p. 1583-1595, 2023. DOI: https://doi.org/10.1007/s12602-022-10039-1
ABID, R. et al. Probiotic yeast Saccharomyces: Back to nature to improve human health. Journal of Fungi, v. 8, n. 444, p. 1-20, 2022. DOI: https://doi.org/10.3390/jof8050444
AGARBATI, A. et al. Potential probiotic yeasts sourced from natural environmental and spontaneous processed foods. Foods, v. 9, n. 287, p. 1-25, 2020. DOI: https://doi.org/10.3390/foods9030287
AHMED, N. et al. Influence of gut microbiome on multiple myeloma: friend or foe?. Journal for Immuno Therapy of Cancer, v. 8, n. 1, p. 1-3, 2020. DOI: https://doi.org/10.1136/jitc-2020-000576
BEDADA, T. L. et al. Probiotics for cancer alternative prevention and treatment. Biomedicine & Pharmacotherapy, v. 129, p. 1-10, 2020. DOI: https://doi.org/10.1016/j.biopha.2020.110409
BREVI, A. et al. Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. Frontiers in Immunology, v. 11, p. 1-19, 2020. DOI: https://doi.org/10.3389/fimmu.2020.565470
BREVI, A. et al. The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma. Frontiers in immunology, v. 13, p. 1-11, 2022. DOI: https://doi.org/10.3389/fimmu.2022.845422
BRIGLE, K.; ROGERS, B. Patobiologia e diagnóstico do mieloma múltiplo. In: Seminários em enfermagem oncológica, p. 225-236, 2017.
CHULUCK, J. B. G. et al. A influência da microbiota intestinal na saúde humana: uma revisão de literatura. Brazilian Journal of Health Review, v. 6, n. 4, p. 16308-16322, 2023. DOI: https://doi.org/10.34119/bjhrv6n4-180
COWAN, A. J. et al. Diagnóstico e manejo do mieloma múltiplo: uma revisão. Jama, v. 5, p. 464-477, 2022.
CURI, R. Glutamina: metabolismo e aplicações clínicas e no esporte. Rio de Janeiro: Sprint, 2000.
DAVIS, L. N.; SHERBENOU, D. W. Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers, v. 13, n. 7, p. 1-21, 2021. DOI: https://doi.org/10.3390/cancers13071686
ESCAMILLA, J.; LANE, M. A.; MAITIN, V. Cell-free supernatants from probiotic Lactobacillus casei and Lactobacillus rhamnosus GG decrease colon cancer cell invasion in vitro. Nutrition and câncer, v. 64, n. 6, p. 871-878, 2012. DOI: https://doi.org/10.1080/01635581.2012.700758
FIGUEIREDO, M. C. F. et al. Efeitos dos probióticos sobre a microbiota intestinal e metabolismo de idosos. Research, Society and Development, v. 9, n. 4, p. 1-16, 2020. DOI: https://doi.org/10.33448/rsd-v9i4.2969
FU, J. et al. Unique probiotic properties and bioactive metabolites of Saccharomyces boulardii. Probiotics and Antimicrobial Proteins, v. 15, n. 4, p. 967-982, 2023. DOI: https://doi.org/10.1007/s12602-022-09953-1
GONÇALVES, M. J. P. et al. Conhecendo o Mieloma Múltiplo: uma revisão de literatura. Revista Científica da Faculdade de Medicina de Campos, v. 18, n. 1, p. 38-43, 2023. DOI: https://doi.org/10.29184/1980-7813.rcfmc.696.vol.18.n1.2023
HILL, C. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol, v. 11, p. 506-514, 2014. DOI: https://doi.org/10.1038/nrgastro.2014.66
JIAN, X. et al. Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome, v. 8, p. 1-21, 2020. DOI: https://doi.org/10.1186/s40168-020-00854-5
KYLE, R. A. et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, v. 378, n. 3, p. 241-249, 2018. DOI: https://doi.org/10.1056/NEJMoa1709974
LANDGREN, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, v. 113, n. 22, p. 5412–5417, 2018. DOI: https://doi.org/10.1182/blood-2008-12-194241
LIU, D. et al. Saccharomyces boulardii alleviates allergic asthma by restoring gut microbiota and metabolic homeostasis via up-regulation of METTL3 in an m6A-dependent manner. Immunology Letters, v. 20, n. 267, p. 1-12, 2024. DOI: https://doi.org/10.1016/j.imlet.2024.106853
LU, K. et al. Probiotics in Cancer. Frontiers in Oncology, v. 11, p. 1-13, 2021. DOI: https://doi.org/10.3389/fonc.2021.638148
MCFARLAND, L. V. Common organisms and probiotics: Saccharomyces boulardii. In: The microbiota in gastrointestinal pathophysiology. [S. l]: Academic Press, 2017. p. 145-164. DOI: https://doi.org/10.1016/B978-0-12-804024-9.00018-5
MEISEL, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature, v. 557, p. 580-584, 2018. DOI: https://doi.org/10.1038/s41586-018-0125-z
MOREIRA, A. et al. Nutritional modulation of exercise-induced immunodepression in athletes: a systematic review and meta-analysis. European Journal of Clinical Nutrition, v. 61, p. 443-60, 2007. DOI: https://doi.org/10.1038/sj.ejcn.1602549
NEWSHOLME, P. et al. Glutamine and glutamate as vital metabolites. Brazilian Journal of Medical and Biological Research, v. 36, p. 153-63, 2003. DOI: https://doi.org/10.1590/S0100-879X2003000200002
ORTUÑO, J. et al. Oral administration of yeast, Saccharomyces cerevisiae, enhances the cellular innat immune response of gilthead seabream (Sparus aurata L.). Veterinary immunology and immunopathology, v. 48, p. 951-960, 2002.
PAGANI, R. N.; KOVALESKI, J. L.; RESENDE, L. M. M. Avanços na composição da Methodi Ordinatio para revisão sistemática de literatura. Ciência da Informação, v. 46, n. 2, p. 161-187, 2017. DOI: https://doi.org/10.18225/ci.inf.v46i2.1886
PAGANI, R. N.; KOVALESKI, J. L.; RESENDE, L. M. M. Methodi Ordinatio: a proposed methodology to select and rank relevant scientific papers encompassing the impact factor, number of citation, and year of publication. Scientometrics, v. 105, p. 2109-2135, 2015. DOI: https://doi.org/10.1007/s11192-015-1744-x
PAGE, M. J. et al. A declaração PRISMA 2020: diretriz atualizada para relatar revisões sistemáticas. Revista Panamericana de Salud Pub., v. 46, p. 1-12, 2023. DOI: https://doi.org/10.26633/RPSP.2022.112
PAKBIN, B. et al. Anticancer properties of probiotic Saccharomyces boulardii supernatant on human breast cancer cells. Probiotics and Antimicrobial Proteins, v. 14, n. 6, p. 1130-1138, 2022. DOI: https://doi.org/10.1007/s12602-021-09756-w
PARSIFAL. Perform Systematic Literature Reviews. [S. l.]: Parsifal, s. d. Disponível em: https://parsif.al/. Acesso em: 20 abr. 2024.
PLATAFORMA SUCUPIRA. Qualis periódicos 2017-2020. Brasilia: Plataforma Sucupira, s. d. Disponível em: https://sucupira.capes.gov.br/. Acesso em: 20 abr. 2024.
RAMAN, M. et al. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut microbes, v. 4, n. 3, p. 181-192, 2013. DOI: https://doi.org/10.4161/gmic.23919
ROGERO, M. M.; TIRAPEGUI, J. O. Considerações nutricionais e bioquímicas da suplementação de glutamina em atletas: controvérsias e aspectos atuais. Journal of Nutrition and Metabolism, v. 7, p. 106-117, 2003.
ROWBOTTOM, D. G.; KEAST, D.; MORTON, A. R. The emerging role of glutamine as an indicator of exercise stress and overtraining. Sports Medicine, v. 21, p. 80-97, 1996. DOI: https://doi.org/10.2165/00007256-199621020-00002
SAADAT, Y. R. et al. Modulatory role of exopolysaccharides of Kluyveromyces marxianus and Pichia kudriavzevii as probiotic yeasts from dairy products in human colon cancer cells. Journal of Functional Foods, v. 64, p. 1-9, 2020. DOI: https://doi.org/10.1016/j.jff.2019.103675
SALEMA, C. L. Z.; CARVALHO, C. Diagnósticos, tratamentos e prognósticos do mieloma múltiplo. Revista Ciência e Saúde On-line, v. 4, n. 1, p. 1-9, 2019.
SAMBRANI, R. et al. Recent advances in the application of probiotic yeasts, particularly Saccharomyces, as an adjuvant therapy in the management of cancer with focus on colorectal cancer. Molecular Biology Reports, v. 48, n. 1, p. 951-960, 2021. DOI: https://doi.org/10.1007/s11033-020-06110-1
SANDERS, M. E.; MARCO, M. L. Food Formats for Effective Delivery of Probiotics. Annual Review of Food Science and Technology, v. 1, p. 65-85, 2010. DOI: https://doi.org/10.1146/annurev.food.080708.100743
SULIK-TYSZKA, B. et al. Experience with Saccharomyces boulardii probiotic in oncohaematological patients. Probiotics and antimicrobial proteins, v. 10, p. 350-355, 2018. DOI: https://doi.org/10.1007/s12602-017-9332-4
TORRES, L. L. et al. Uma análise acerca das características do Mieloma Múltiplo: revisão de literatura. Revista Eletrônica Acervo Médico, v. 15, p. 1-6, 2022. DOI: https://doi.org/10.25248/reamed.e10723.2022
WAITZBERG, D. et al. Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?. Advances in Therapy, v. 41, n. 3, p. 901-914, 2024. DOI: https://doi.org/10.1007/s12325-024-02783-3
WANG, Y. et al. Intestinal Klebsiella pneumoniae contributes to pneumonia by synthesizing glutamine in multiple myeloma. Cancers, v. 14, p. 1-17, 2022. DOI: https://doi.org/10.3390/cancers14174188
WEI, Y. et al. Antifungal bio-coating of endotracheal tube built by overexpressing the MCP1 gene of Saccharomyces boulardii and employing hydrogel as a “house” to antagonize Candida albicans. Biomaterials Research, v. 27, n. 1, p. 1-16, 2023. DOI: https://doi.org/10.1186/s40824-023-00443-1
WU, X. et al. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. British Journal of Haematology, v. 190, p. 52-66, 2020. DOI: https://doi.org/10.1111/bjh.16503
XIA, J. et al. Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. Nature Communications, v. 13, p. 1-16, 2022. DOI: https://doi.org/10.1038/s41467-022-31248-w
YE, H. et al. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell, v. 34, p. 659-673, 2018. DOI: https://doi.org/10.1016/j.ccell.2018.08.016
ZHOU, J.; CHNG, W. J. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World Journal of Clinical Oncology, v. 10, n. 9, p. 1-5, 2019. DOI: https://doi.org/10.5306/wjco.v10.i9.303
ZHU, Y. et al. Intestinal microbes and hematological malignancies. Cancers, v. 15, n. 8, p. 1-16, 2023. DOI: https://doi.org/10.3390/cancers15082284
ZHU, Y. et al. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metabolism, v. 36, n. 1, p. 159-175, 2024. DOI: https://doi.org/10.1016/j.cmet.2023.11.019
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
